Recent data on noninvasive tests for nonalcoholic fatty liver disease (NAFLD)/nonalcoholic steatohepatitis (NASH) were presented at The Liver Meeti......READ MORE
Given the prevalence and clinical significance of nonalcoholic fatty liver disease (NAFLD), there is a growing call for multidisciplinary care. Opp......READ MORE
The gut-liver axis is an important component in the development of alcohol-associated liver disease (ALD), as discussed at The Liver Meeting® 2021.......READ MORE
Recent data on novel approaches for detecting liver disease were presented at The Liver Meeting® 2021. Ashwani K. Singal, MD, MS, AGAF, FACG, FAASL......READ MORE
Agents in development to treat nonalcoholic steatohepatitis (NASH) are beginning to be tested in phase 3 clinical trials, suggesting that treatment......READ MORE
Biopsy remains the gold standard for diagnosing nonalcoholic steatohepatitis (NASH). However, the great need for noninvasive tests to risk stratify......READ MORE
